Papers/PMID:19390751
Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly.
The journal of nutrition, health & aging2009The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
riboflavin — decreases erythrocyte glutathione reductase activation coefficient (EGRac)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Riboflavin supplementation significantly decreased plasma tHcy (P=0.005) and EGRAC (P=0.014), but not plasma ferritin, uric acid or C-reactive protein.”
Quoted verbatim from Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly.. - Study
- RCT
- Participants
- 42
- Duration
- 4 weeks
- Dose
- 10 mg riboflavin per day orally vs placebo
- Population
- Portuguese elderly people aged 60-94 years with low riboflavin status (EGRAC of 1.2 or more) attending day social centres
Riboflavin supplementation and biomarkers of cardiovascular disease in the elderly.2009PMID:19390751Permalink